Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | Clinical management of myeloma: vaccination, novel therapeutic agents and more at COMy 2022

Mohamad Mohty • 28 Feb 2022
COMy 2022
Multiple Myeloma Antibodies

In this video, Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, mentions some of the discussions that will be held at COMy 2022, including the COVID-19 vaccine and management of infections in myeloma patients, as well as the side effects of novel therapeutic agents including anti-CD38 antibodies, bispecific antibodies, and proteasome inhibitors.

More from Mohamad Mohty

2:24
Comparing alloSCT outcomes in secondary and de-novo acute lymphoblastic leukemia
Mohamad Mohty • 15 Feb 2024
4:17
The evolving role of autoSCT in the age of CAR-T for multiple myeloma: current & future perspectives
Mohamad Mohty • 15 Feb 2024
4:02
Moving CAR-T therapy into earlier lines of treatment for myeloma and the need for effective bridging
Mohamad Mohty • 15 Feb 2024
4:04
Overcoming challenges in CAR T-cell therapy for multiple myeloma
Mohamad Mohty • 15 Feb 2024

Related Videos

2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals